Mark Erlander
CIK 1651537 · Chief Executive Officer · last filed 2025-03-13
Mark Erlander is a Chief Executive Officer who has filed 31 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing, for CRDF, was dated Mar 13, 2025. Across all open-market trades the lifetime net is +$44.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $37.7K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$37.7K
3
31
$44.7K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRDF | Chief Executive Officer | 24,481 | $1.54 | $37.7K | $34.3K | 10 | 2025-03-13 |
| Cardiff Oncology, Inc. (TROV) Delisted | Chief Scientific Officer | 6,231 | — | — | $0 | 16 | 2020-01-03 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Chief Scientific Officer | 55,000 | — | — | $10.4K | 5 | 2017-04-10 |
Recent Filings
31 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-13 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2024-03-07 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2023-03-16 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2022-11-29 | CRDF | Buy (P) | +10,000 | $14.3K | EDGAR |
| 2022-03-10 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2021-06-14 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2021-03-23 | CRDF | Buy (P) | +965 | $10.0K | EDGAR |
| 2021-01-05 | CRDF | Mixed | +147 | $0 | EDGAR |
| 2020-06-19 | CRDF | Grant (A) | — | $0 | EDGAR |
| 2020-05-18 | CRDF | Buy (P) | +6,993 | $10.0K | EDGAR |